Echo Therapeutics has initiated a clinical study of its Symphony transdermal continuous glucose monitoring (tCGM) system in patients with Type 1 and Type 2 diabetes.
The Symphony tCGM system is a non-invasive, wireless, transdermal continuous glucose monitoring system for diabetic patients.
The study is expected to enroll up to 25 patients with either Type 1 or Type 2 diabetes and will compare data obtained from its Symphony tCGM system with both the YSI 2300 STAT Plus glucose analyser and a commercially available professional-use glucometer.
The study will collect more than 2,400 data pairs to be used in the analyses by taking frequent reference glucose measurements for 24 hours, to assess the accuracy of Symphony.
Echo Therapeutics chairman and CEO Patrick Mooney said the trial is an important step not only for Echo's glucose monitoring technology and the company, but also for the diabetes community.
''We believe that Symphony represents an opportunity to better monitor glucose levels in people with diabetes and we look forward to confirming this in the trial," Mooney said.
The company expects to complete and announce the results of the study in Q4 2011 and plans to subsequently begin a separate study in critical care patients.